Sun Pharma's growth pill: Specialising in specialty and scaling in India

Traction for its specialty portfolio, a strong showing in the domestic market, and better regulatory compliance are positives for the country’s largest pharmaceutical (pharma) company, Sun......

Sun Pharma's growth prospects look healthy; analysts positive on the stock

Sun Pharmaceutical Industries (Sun Pharma) reported a turnaround in the January-March quarter of the 2022-23 financial year (Q4FY23), declaring a profit after tax (PAT) of Rs 1,984 crore versus a......

Israel conflict unlikely to impact trade of pharma firms

Indian pharmaceutical firms foresee minimal disruptions in trade with Israel despite escalating regional tensions. Photograph: Yves Herman/Reuters Rising crude prices and export shipping insurance......

Taro accuses Sun of waging proxy war

Israeli drug maker Taro Pharma has alleged that Sun Pharma is attempting to seize its control by waging a proxy war. Seeking the support of its shareholders, Taro chairman and managing director......